Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001056123 | SCV001220544 | uncertain significance | Amelocerebrohypohidrotic syndrome | 2022-09-07 | criteria provided, single submitter | clinical testing | This sequence change replaces methionine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 231 of the ROGDI protein (p.Met231Val). This variant is present in population databases (rs137934107, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with ROGDI-related conditions. ClinVar contains an entry for this variant (Variation ID: 851681). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
New York Genome Center | RCV001056123 | SCV002506834 | uncertain significance | Amelocerebrohypohidrotic syndrome | 2021-05-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002553362 | SCV003666751 | uncertain significance | Inborn genetic diseases | 2021-11-08 | criteria provided, single submitter | clinical testing | The c.691A>G (p.M231V) alteration is located in exon 9 (coding exon 9) of the ROGDI gene. This alteration results from a A to G substitution at nucleotide position 691, causing the methionine (M) at amino acid position 231 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |